163 related articles for article (PubMed ID: 24158003)
1. Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells.
Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Lee SR; Ko TH; Youm JB; Kim N; Ko KS; Rhee BD; Han J
Exp Mol Med; 2013 Oct; 45(10):e50. PubMed ID: 24158003
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.
Song IS; Kim HK; Lee SR; Jeong SH; Kim N; Ko KS; Rhee BD; Han J
Int J Cancer; 2013 Sep; 133(6):1357-67. PubMed ID: 23463417
[TBL] [Abstract][Full Text] [Related]
3. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Yu C; Rahmani M; Dent P; Grant S
Exp Cell Res; 2004 May; 295(2):555-66. PubMed ID: 15093752
[TBL] [Abstract][Full Text] [Related]
4. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
[TBL] [Abstract][Full Text] [Related]
5. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
8. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Ling YH; Liebes L; Zou Y; Perez-Soler R
J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
[TBL] [Abstract][Full Text] [Related]
10. Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
Gauduchon J; Seguin A; Marsaud V; Clay D; Renoir JM; Sola B
Int J Cancer; 2008 May; 122(9):2130-41. PubMed ID: 18183592
[TBL] [Abstract][Full Text] [Related]
11. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
12. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
Yin L; Kufe T; Avigan D; Kufe D
Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
[TBL] [Abstract][Full Text] [Related]
13. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism associated to enhancing the sensitivity of myeloma cells U266 to bortezomib by 2-methoxyestradiol].
Wu SQ; Xu ZZ; Huang HB; Lin J; Zhan R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1424-8. PubMed ID: 22169296
[TBL] [Abstract][Full Text] [Related]
16. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.
Selimovic D; Porzig BB; El-Khattouti A; Badura HE; Ahmad M; Ghanjati F; Santourlidis S; Haikel Y; Hassan M
Cell Signal; 2013 Jan; 25(1):308-18. PubMed ID: 23079083
[TBL] [Abstract][Full Text] [Related]
19. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
Lauricella M; Emanuele S; D'Anneo A; Calvaruso G; Vassallo B; Carlisi D; Portanova P; Vento R; Tesoriere G
Apoptosis; 2006 Apr; 11(4):607-25. PubMed ID: 16528474
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]